Table of Contents

FAIM-L Is an IAP-Binding Protein That Inhibits XIAP Ubiquitinylation and Protects from Fas-Induced Apoptosis

  1. Joan X. Comella1,2,3
  1. 1Institut de Recerca de l'Hospital Universitari de la Vall d'Hebron (VHIR), 08035 Barcelona, Spain,
  2. 2Institut de Neurociències, Departament de Bioquímica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra Spain,
  3. 3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Spain,
  4. 4Departament de Ciències Experimentals i de la Salut, Cell Signalling Unit, Universitat Pompeu Fabra, 08003 Barcelona, Spain,
  5. 5Laboratoris Clinics, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain, and
  6. 6Institut de Recerca Biomèdica de Lleida, Universitat de Lleida, 25198 Lleida, Spain
  1. Author contributions: R.S.M., M.F.S., C.S., and J.X.C. designed research; R.S.M., L.P.-F., J.U., P.C., F.M.-F., C.S., and D.S. performed research; R.S.M., L.P.-F., S.R., and J.L.-S. contributed unpublished reagents/analytic tools; R.S.M., L.P.-F., M.F.S., N.L.-C., V.J.Y., and J.X.C. analyzed data; R.S.M. and J.X.C. wrote the paper.

Abstract

The neuronal long isoform of Fas Apoptotic Inhibitory Molecule (FAIM-L) protects from death receptor (DR)-induced apoptosis, yet its mechanism of protection remains unknown. Here, we show that FAIM-L protects rat neuronal Type II cells from Fas-induced apoptosis. XIAP has previously emerged as a molecular discriminator that is upregulated in Type II and downregulated in Type I apoptotic signaling. We demonstrate that FAIM-L requires sustained endogenous levels of XIAP to protect Type II cells as well as murine cortical neurons from Fas-induced apoptosis. FAIM-L interacts with the BIR2 domain of XIAP through an IAP-binding motif, the mutation of which impairs the antiapoptotic function of FAIM-L. Finally, we report that FAIM-L inhibits XIAP auto-ubiquitinylation and maintains its stability, thus conferring protection from apoptosis. Our results bring new understanding of the regulation of endogenous XIAP by a DR antagonist, pointing out at FAIM-L as a promising therapeutic tool for protection from apoptosis in pathological situations where XIAP levels are decreased.

  • Received June 12, 2013.
  • Revision received October 11, 2013.
  • Accepted October 31, 2013.